Catalog No.
RHN06001
Species reactivity
Human
Host species
Mouse
Isotype
IgG2a, kappa
Clonality
Monoclonal
Target
Serologically defined breast cancer antigen NY-BR-1, ANKRD30A, Ankyrin repeat domain-containing protein 30A
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q9BXX3
Applications
ELISA
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
SAA1895
In-depth proteomic analysis identifies key gene signatures predicting therapeutic efficacy of anti-PD-1/PD-L1 monotherapy in non-small cell lung cancer., PMID:38405006
A 10-Gene Signature for Predicting the Response to Neoadjuvant Trastuzumab Therapy in HER2-Positive Breast Cancer., PMID:34052107
NY-BR-1 Antigen Expression and anti-NY-BR-1 IgG in Egyptian Breast Cancer Patients: Clinicopathological and Prognostic Significance., PMID:26415367
NY-BR-1 is a differentiation antigen of the mammary gland., PMID:17536312
NY-BR-1 protein expression in breast carcinoma: a mammary gland differentiation antigen as target for cancer immunotherapy., PMID:17410359
The differentiation antigen NY-BR-1 is a potential target for antibody-based therapies in breast cancer., PMID:17330232
Preferential nuclear and cytoplasmic NY-BR-1 protein expression in primary breast cancer and lymph node metastases., PMID:16675566
Humoral and cellular immune responses against the breast cancer antigen NY-BR-1: definition of two HLA-A2 restricted peptide epitopes., PMID:16335914
For research use only. Not for human or drug use.
